Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol
2024 · The Lancet Regional Health - Europe · 26 citations
https://doi.org/10.1016/j.lanepe.2024.100875
K
Karlijn Verkerk
Oncode Institute(NL)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
57
Papers
82
Citations
4
h-index
3
i10-index
Karlijn Verkerk is an academic researcher from Oncode Institute. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & HER2/EGFR in Cancer Research & Lung Cancer Treatments and Mutations. The author has an h-index of 4, co-authored 49 publications.
ORCID: 0000-0002-5882-4980Papers by this author
worksTrastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP)
2024 · European Journal of Cancer · 14 citations
https://doi.org/10.1016/j.ejca.2024.113988
The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)
2025 · ESMO Open · 4 citations
https://doi.org/10.1016/j.esmoop.2024.104112
Liver metastases dampen IL18-driven γδ T cell activity and immunotherapy responsiveness in colorectal cancer
2026 · Cell Reports Medicine · 1 citations
https://doi.org/10.1016/j.xcrm.2025.102579
Figure S1. Accrual and follow-up1 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol
2024 · 0 citations
https://doi.org/10.1158/1078-0432.27938425
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat